On 20 December, the Washington University School of Medicine in St. Louis announced that it will launch an international primary prevention trial for people who have inherited rare genetic mutations that predispose them to early-onset Alzheimer’s disease.
The new trial will investigate whether gantenerumab (an antibody that binds and clears amyloid beta proteins) can prevent familial Alzheimer’s disease, in young participants who have no or very few amyloid deposits in the brain. Led by Prof. Eric McDade, and supported by Roche, Genentech and grants from the National Institutes of Health, the Alzheimer’s Association and philanthropic funders, the trial will last 4 years and aims to recruit 230 participants from families with genetic mutations leading to early-onset Alzheimer’s disease.
https://medicine.wustl.edu/news/new-alzheimers-prevention-trial-in-young-people/
